EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieVergleichsstudieOpen Access · CC BY-NC 4.0

Methods of nivolumab administration in advanced melanoma: A comparison of patients’ clinical outcomes treated with flat dose or weight‐adjusted dose, a multicenter observational study

Iona Campo Le Brun, Séphane Dalle, Laurent Mortier, Olivier Dereure, Sophie Dalac Rat, Caroline Dutriaux, Marie-Thérèse Leccia, Delphine Legoupil, Henri Montaudié, Julie De Quatrebarbes, Caroline Gaudy-Marqueste, Eve Maubec und 8 weitere

Cancer · 2025

DOI: 10.1002/cncr.35679 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer, 2025. Verfasst von Iona Campo Le Brun und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Créteil, France. Hauptthemen laut MEDLINE: Nivolumab, Melanoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nivolumab obtained approval in advanced melanoma (AM) with weight‐adjusted dose (WAD) administration (3 mg/kg/2 weeks). In 2018, the dosage regimen was changed to flat dose (FD) administration (240 mg/2 weeks or 480 mg/4 weeks) based on a modeling study, without clinical data.

Methods

AM patients have been prospectively included in the French national multicenter MelBase database since 2013. First‐line patients treated with nivolumab monotherapy were included in the WAD or FD groups of this study. The primary end point was the incidence of grade ≥3 immune‐related adverse events (irAEs). Secondary end points were incidence of any grade irAEs, and overall survival (OS) and progression‐free survival (PFS). Inverse probability of treatment weighting was used to balance groups on their baseline characteristics.

Results

Between 2015 and 2022, 348 patients were included: 160 in the WAD and 188 in the FD groups. In the FD group, 45% and 27% of patients weighed 85 kg, respectively. Grade ≥3 and any grade irAEs rates were 13.1% versus 11.7% ( p = .8) and 63.1% versus 67.0% ( p = .5) in the WAD and FD groups, respectively. After weighting, median PFS was 3.1 and 3.7 months (hazard ratio [HR], 0.84; 95% confidence interval [CI], 0.65–1.07), and median OS was 24.8 and 37.0 months (HR, 0.74; 95% CI, 0.54–1.01) in the WAD and FD groups, respectively.

Conclusions

There was no difference in the incidence of severe irAEs and in median PFS between AM patients treated by WAD or FD nivolumab. The median OS between patient groups did not reach statistical significance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabMelanomaHumansFemaleMaleMiddle AgedAgedAdultProspective StudiesProgression-Free SurvivalSkin NeoplasmsBody WeightTreatment OutcomeAged, 80 and overAntineoplastic Agents, ImmunologicalFranceDose-Response Relationship, DrugImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

delivery of health caredose–response relationshipdrughealth services researchimmune checkpoint inhibitorsmelanoma

Substanzen

NivolumabAntineoplastic Agents, ImmunologicalImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Créteil, France.
  • INSERM 1052, Department of Dermatology, Hospices Civils de Lyon, Lyon-Sud hospital Pierre-Benite, Lyon University, Claude Bernard Lyon 1 University, CNRS 5286, Léon Bérard center, Cancer Research Center of Lyon, Lyon, F…
  • INSERM U1189, Department of Dermatology, Lille University Hospital, Université de Lille, Lille, France.
  • INSERM U1058, Department of Dermatology, University of Montpellier, Montpellier, France.
  • Department of Dermatology, Dijon Bourgogne University Hospital, Dijon, France.
  • Department of Dermatology, Saint André Hospital, Bordeaux, France.

ORCID-Profile: Célèste Lebbé, Emmanuelle Kempf

Zitieren

APA

Le Brun, I. C., Dalle, S., Mortier, L., Dereure, O., Rat, S. D., Dutriaux, C., Leccia, M. T., Legoupil, D., Montaudié, H., De Quatrebarbes, J., Gaudy-Marqueste, C., Maubec, E., Saiag, P., Pagès, C., Possenti, F. B., Granel-Brocard, F., Porcher, R., Lefevre, W., Lebbé, C., & Kempf, E. (2025). Methods of nivolumab administration in advanced melanoma: A comparison of patients’ clinical outcomes treated with flat dose or weight‐adjusted dose, a multicenter observational study. Cancer. https://doi.org/10.1002/cncr.35679

Vancouver

Le Brun IC, Dalle S, Mortier L, Dereure O, Rat SD, Dutriaux C, et al. Methods of nivolumab administration in advanced melanoma: A comparison of patients’ clinical outcomes treated with flat dose or weight‐adjusted dose, a multicenter observational study. Cancer. 2025. doi:10.1002/cncr.35679

BibTeX
@article{LeBrun2025,
  author = {Le Brun, Iona Campo and Dalle, Séphane and Mortier, Laurent and Dereure, Olivier and Rat, Sophie Dalac and Dutriaux, Caroline and Leccia, Marie-Thérèse and Legoupil, Delphine and Montaudié, Henri and De Quatrebarbes, Julie and Gaudy-Marqueste, Caroline and Maubec, Eve and Saiag, Philippe and Pagès, Cécile and Possenti, Florence Brunet and Granel-Brocard, Florence and Porcher, Raphaël and Lefevre, Wendy and Lebbé, Célèste and Kempf, Emmanuelle},
  title = {Methods of nivolumab administration in advanced melanoma: A comparison of patients’ clinical outcomes treated with flat dose or weight‐adjusted dose, a multicenter observational study},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.35679}
}
Kostenlos starten →